Cilostazol After Lower Extremity Arterial Revascularization Trial

Summary

Twenty patients will be recruited to CLEAR. Ten will be randomized to the treatment arm (Cilostazol) and tenwill be randomized to the control group. Patients randomized to the treatment arm will receive Cilostazol for 90 days. The primary purpose of this study is to collect quality of life data on patients undergoing peripheral revascularization in order to determine the sample size required to adequately power a trial of Cilostazol versus usual care without Cilostazol and its effect on quality of life.

Timeline

Start

2015-02

Primary completion

2017-06-30

Completion

2017-06-30

Drugs

Indications